Cover Image
市場調查報告書

Richter Gedeon Nyrt.- 產品平台檢討

Richter Gedeon Nyrt. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 269909
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
Richter Gedeon Nyrt.- 產品平台檢討 Richter Gedeon Nyrt. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 38 Pages
簡介

Richter Gedeon Nyrt.是總公司設在匈牙利的製藥企業,進行品牌藥,非專利,許可證產品,成藥等各種產品的開發、製造、商品化。對象領域為婦產科系統疾病、心血管系統疾病、消化器官系統疾病、中樞神經系統疾病等。由獨有銷售網銷售產品至100個以上的國家。

本報告提供Richter Gedeon Nyrt.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Richter Gedeon Nyrt.的基本資料

  • Richter Gedeon Nyrt.概要
  • 主要資訊
  • 企業資料

Richter Gedeon Nyrt.:R&D概要

  • 主要的治療範圍

Richter Gedeon Nyrt.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Richter Gedeon Nyrt.:開發中產品概況

  • 後期階段的開發中產品
    • 申請前階段的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Richter Gedeon Nyrt.:藥物簡介

  • cariprazine
  • pegfilgrastim
  • Small Molecule for Undisclosed Indication
  • rituximab biosimilar
  • trastuzumab biosimilar
  • teriparatide biosimilar

Richter Gedeon Nyrt.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Richter Gedeon Nyrt.:最近的開發平台資訊

Richter Gedeon Nyrt.:開發暫停中的計劃

Richter Gedeon Nyrt.:開發中止的產品

Richter Gedeon Nyrt.:企業理念

Richter Gedeon Nyrt.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07099CDB

Summary

Global Markets Direct's, 'Richter Gedeon Nyrt. - Product Pipeline Review - 2015', provides an overview of the Richter Gedeon Nyrt.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Richter Gedeon Nyrt.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Richter Gedeon Nyrt. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Richter Gedeon Nyrt.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Richter Gedeon Nyrt.'s pipeline products

Reasons to buy

  • Evaluate Richter Gedeon Nyrt.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Richter Gedeon Nyrt. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Richter Gedeon Nyrt.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Richter Gedeon Nyrt. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Richter Gedeon Nyrt.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Richter Gedeon Nyrt. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Richter Gedeon Nyrt. Snapshot
    • Richter Gedeon Nyrt. Overview
    • Key Information
    • Key Facts
  • Richter Gedeon Nyrt. - Research and Development Overview
    • Key Therapeutic Areas
  • Richter Gedeon Nyrt. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Richter Gedeon Nyrt. - Pipeline Products Glance
    • Richter Gedeon Nyrt. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Richter Gedeon Nyrt. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Richter Gedeon Nyrt. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Richter Gedeon Nyrt. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Richter Gedeon Nyrt. - Drug Profiles
    • cariprazine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teriparatide biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Richter Gedeon Nyrt. - Pipeline Analysis
    • Richter Gedeon Nyrt. - Pipeline Products by Target
    • Richter Gedeon Nyrt. - Pipeline Products by Route of Administration
    • Richter Gedeon Nyrt. - Pipeline Products by Molecule Type
    • Richter Gedeon Nyrt. - Pipeline Products by Mechanism of Action
  • Richter Gedeon Nyrt. - Recent Pipeline Updates
  • Richter Gedeon Nyrt. - Dormant Projects
  • Richter Gedeon Nyrt. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • radiprodil
      • RGH-512
  • Richter Gedeon Nyrt. - Company Statement
  • Richter Gedeon Nyrt. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Richter Gedeon Nyrt., Key Information
  • Richter Gedeon Nyrt., Key Facts
  • Richter Gedeon Nyrt. - Pipeline by Indication, 2015
  • Richter Gedeon Nyrt. - Pipeline by Stage of Development, 2015
  • Richter Gedeon Nyrt. - Monotherapy Products in Pipeline, 2015
  • Richter Gedeon Nyrt. - Pre-Registration, 2015
  • Richter Gedeon Nyrt. - Phase III, 2015
  • Richter Gedeon Nyrt. - Phase II, 2015
  • Richter Gedeon Nyrt. - Preclinical, 2015
  • Richter Gedeon Nyrt. - Discovery, 2015
  • Richter Gedeon Nyrt. - Unknown, 2015
  • Richter Gedeon Nyrt. - Pipeline by Target, 2015
  • Richter Gedeon Nyrt. - Pipeline by Route of Administration, 2015
  • Richter Gedeon Nyrt. - Pipeline by Molecule Type, 2015
  • Richter Gedeon Nyrt. - Pipeline Products by Mechanism of Action, 2015
  • Richter Gedeon Nyrt. - Recent Pipeline Updates, 2015
  • Richter Gedeon Nyrt. - Dormant Developmental Projects,2015
  • Richter Gedeon Nyrt. - Discontinued Pipeline Products, 2015
  • Richter Gedeon Nyrt., Other Locations
  • Richter Gedeon Nyrt., Subsidiaries

List of Figures

  • Richter Gedeon Nyrt. - Pipeline by Top 10 Indication, 2015
  • Richter Gedeon Nyrt. - Pipeline by Stage of Development, 2015
  • Richter Gedeon Nyrt. - Monotherapy Products in Pipeline, 2015
  • Richter Gedeon Nyrt. - Pipeline by Top 10 Target, 2015
  • Richter Gedeon Nyrt. - Pipeline by Top 10 Route of Administration, 2015
  • Richter Gedeon Nyrt. - Pipeline by Top 10 Molecule Type, 2015
  • Richter Gedeon Nyrt. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top